Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ulrike Dirmeier
Observed names:
Dirmeier, Ulrike,
U Dirmeier
Institution:
Bavarian Nordic (Germany)
Observed institutions:
Helmholtz Munich,
Bavarian Nordic (Germany),
Ludwig-Maximilians-Universität München
OpenAlex ID:
A5055083900
Active NF-κB signalling is a prerequisite for influenza virus infection
2004
·
Falk Nimmerjahn
, Diana Dudziak
, et al.
·
Journal of General Virology
·
225
Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.
2003
·
Ulrike Dirmeier
, Bernhard Neuhierl
, et al.
·
PubMed
·
174
Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy
2011
·
Ryan B. Rountree
, Stefanie J. Mandl
, et al.
·
Cancer Research
·
165
PDF
Latent membrane protein 1 of Epstein–Barr virus coordinately regulates proliferation with control of apoptosis
2005
·
Ulrike Dirmeier
, Reinhard Hoffmann
, et al.
·
Oncogene
·
164
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
2018
·
Benoit Callendret
, Jort Vellinga
, et al.
·
PLoS ONE
·
98
PDF
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
2017
·
Christopher R. Heery
, Claudia Palena
, et al.
·
Clinical Cancer Research
·
70
The Synechococcus Strain PCC 7942 glnN Product (Glutamine Synthetase III) Helps Recovery from Prolonged Nitrogen Chlorosis
2000
·
Jörg Sauer
, Ulrike Dirmeier
, et al.
·
Journal of Bacteriology
·
66
Introduction of the Six Major Genomic Deletions of Modified Vaccinia Virus Ankara (MVA) into the Parental Vaccinia Virus Is Not Sufficient To Reproduce an MVA-Like Phenotype in Cell Culture and in Mice
2010
·
Christine Meisinger-Henschel
, Michaela Späth
, et al.
·
Journal of Virology
·
63
Latent Membrane Protein 1 of Epstein-Barr Virus Induces CD83 by the NF-κB Signaling Pathway
2003
·
Diana Dudziak
, Arnd Kieser
, et al.
·
Journal of Virology
·
63
A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses
2013
·
Sonia T. Wennier
, Kay Brinkmann
, et al.
·
PLoS ONE
·
32
PDF
Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine
2018
·
Martinus A.H. Capelle
, Lara Babich
, et al.
·
European Journal of Pharmaceutics and Biopharmaceutics
·
29
Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells
2011
·
Stefanie J. Mandl
, Ryan B. Rountree
, et al.
·
Cancer Immunology Immunotherapy
·
28
PDF
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles
2017
·
Marc Schweneker
, Andrea S. Laimbacher
, et al.
·
Journal of Virology
·
27
PDF
A poxviral-based cancer vaccine targeting the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
2015
·
Anna R. Kwilas
, Andressa Ardiani
, et al.
·
Oncotarget
·
27
PDF
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
2018
·
Benoit Callendret
, Jort Vellinga
, et al.
·
PLoS ONE
·
16
PDF
Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
2015
·
Christopher R Heery
, Renee Donahue
, et al.
·
Journal for ImmunoTherapy of Cancer
·
5
PDF
P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response
2009
·
T Overton
, D Schmidt
, et al.
·
Retrovirology
·
1
PDF
Figure S1 from Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
2023
·
Christopher R. Heery
, Claudia Palena
, et al.
PDF
Data from Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
2023
·
Christopher R. Heery
, Claudia Palena
, et al.
Figure S1 from Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
2023
·
Christopher R. Heery
, Claudia Palena
, et al.
Supplementary Figure 1 from Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy
2023
·
Ryan B. Rountree
, Stefanie J. Mandl
, et al.
Supplementary Figure 2 from Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy
2023
·
Ryan B. Rountree
, Stefanie J. Mandl
, et al.
Supplementary Figure 2 from Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy
2023
·
Ryan B. Rountree
, Stefanie J. Mandl
, et al.
PDF
Data from Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy
2023
·
Ryan B. Rountree
, Stefanie J. Mandl
, et al.
Data from Exosome Targeting of Tumor Antigens Expressed by Cancer Vaccines Can Improve Antigen Immunogenicity and Therapeutic Efficacy
2023
·
Ryan B. Rountree
, Stefanie J. Mandl
, et al.
Show more works
View as search
Works count:
26
Citation count:
1,253
H-index:
15
I10-index:
15
Year
Topic
Type